Vaduz Liechtenstein Charlevoix Sovereign Strategic Investment Fund
Additional shared vehicles: SV Life Sciences Fund VI, L.P. (2025 Vintage) · Sapphire Emerging Ventures VII (2025 Vintage)
$6.0B Total AUM · Institutional LP profile covering 27 historical fund disclosure records ($769.9M parsed USD across disclosed rows) across disclosed strategy exposure in Buyout, Venture Capital, Private Equity, Secondaries, Multi-Strategy (investment geography mandates are evaluated separately from LP headquarters). 5 complete primary source trails are open below without registration.
Showing 5 open preview records out of 27 total tracked records (+22 gated pilot rows). Click Inspect Source on any row to view field-level substantiation, table headers/units, and archived page excerpts without login.
| Disclosed Fund / Vehicle | Strategy | Fund Vintage | Advised Vehicle GAV | Disclosed Performance | Primary Source Trail |
|---|---|---|---|---|---|
| SEI Secondary Opportunities Fund I, LPAdviser 7.B Vehicle | Secondaries | 2025 |
$46.0M
Adviser-managed fund GAV · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
| SEI Global Private Asset Fund VI, LPAdviser 7.B Vehicle | Buyout | 2025 |
$43.0M
Adviser-managed fund GAV · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
| SV Life Sciences Fund VI, L.P.Adviser 7.B Vehicle | Buyout | 2025 |
$41.0M
Adviser-managed fund GAV · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
| Sapphire Emerging Ventures VIIAdviser 7.B Vehicle | Venture Capital | 2025 |
$35.5M
Adviser-managed fund GAV · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
| SV Biotech Crossover Opportunities Fund, L.P.Adviser 7.B Vehicle | Buyout | 2025 |
$21.8M
Adviser-managed fund GAV · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
Tracked separately from historical commitments: active RFPs/searches, board pacing plans, leadership/CIO updates, and retained gatekeeper consultants.
Delmarva Fauquier Livingston Multi-Family Office Private Capital Platform (Family Office / MFO, $6.0B AUM): Disclosed FY2025-2026 Private Markets Pacing & Allocation Update (PE Target 26.0% vs. 23.8% Actual; $132.0M Unallocated Target Bandwidth). Active FY2025–2026 Private Markets Pacing: Deploying ~$59M–$112M/yr across 4–8 institutional GP fund commitments (Target PE Allocation 26.0% vs 23.8% actual on $6.0B total assets). Gatekeeper / Intake Conduit: Internal Investment Office.
Forward-looking board pacing or target-allocation policy update · Recorded 2025-01-06
Board-Approved Pacing Plans, Active RFPs & Target-vs-Actual Allocation Gap
Join waitlist for pacing dossier →
Retained Private Markets Advisors & Emerging-Manager Search Conduits
Join waitlist for consultant map →
CIO, Private Markets Officers & Official Pitch Intake Guidance
Join waitlist for team directory →
You are viewing 5 open public preview records (out of 27 total tracked records for Delmarva Fauquier Livingston Multi-Family Office Private Capital Platform) with zero-registration primary source trails. Join the early-access waitlist to request pilot access:
Enter your firm email to request pilot onboarding for Delmarva Fauquier Livingston Multi-Family Office Private Capital Platform and our interactive GP workspace.
Thank you for joining the Prilago early-access waitlist! We will reach out with pilot access details for your firm.
Delmarva Fauquier Livingston Multi-Family Office Private Capital Platform is categorized under Family Office / MFO (Regional Roadshow Hub: New York / Tri-State; Headquarters: Dover, DE). Across 27 historical disclosure records tracked on Prilago ($769.9M total parsed USD across disclosed rows), the median disclosed amount is $21.8M (range: $13.0M to $57.4M).
Delmarva Fauquier Livingston Multi-Family Office Private Capital Platform has disclosed records across Buyout, Venture Capital, Private Equity, Secondaries, Multi-Strategy. Open preview records include SEI Secondary Opportunities Fund I, LP (2025 Vintage), SEI Global Private Asset Fund VI, LP (2025 Vintage), SV Life Sciences Fund VI, L.P. (2025 Vintage), Sapphire Emerging Ventures VII (2025 Vintage).
Records for Delmarva Fauquier Livingston Multi-Family Office Private Capital Platform cite primary public disclosures (SEC Form ADV 7.B), and visitors can inspect 5 open source trails on this profile without registration. Each source trail displays field-level substantiation status, distinguishing exact commitment schedules from carrying-value or fee tables. Forward-looking active searches, RFPs, pacing plans, and governance updates are separated from historical disclosures.
General Partners can join the early-access waitlist on https://prilago.com/lp/delmarva-fauquier-livingston-multi-family-office-private-capital-platform or test fund suitability in the interactive read-only demo at https://prilago.com/demo.
In Prilago's bilateral commitment graph, Delmarva Fauquier Livingston Multi-Family Office Private Capital Platform shares resolved underlying fund vehicles with 605 institutional LPs across 27 shared vehicles (shared fund exposure represents a potential introduction path and does not prove LPAC seat overlap or personal acquaintance). Top shared-fund peers include Vaduz Liechtenstein Charlevoix Sovereign Strategic Investment Fund (12 shared vehicles, e.g. SEI Secondary Opportunities Fund I, LP (2025 Vintage)), Fairfield County Hopewell Pendleton Institutional Outsourced CIO & Wealth Advisory (11 shared vehicles, e.g. SV Life Sciences Fund VI, L.P. (2025 Vintage)), Carrabassett Cape Fear Bellingham Mutual & Casualty Insurance General Account (10 shared vehicles, e.g. Sapphire Emerging Ventures VII (2025 Vintage)).